Abstract
Objective: To study the immunoregulation and mechanism of entecavir for patients with HBeAg-positive chronic hepatitis B.
Methods: Thirty patients with HBeAg-positive chronic hepatitis B took 0.5 mg entecavir every day. Then we detected the levels of serum HBVDNA, IFN-γ, IL-4 and B7-H1 mRNA of PBMCs in baseline at12, 24, 48 and weeks, respectively.
Results: ① The level of B7-H1 mRNA of PBMCs after treatment decreased progressively in responding group, with a significant difference (P=0.005). It decreased slowly in non-responding group, without significant difference (P=0.466). ② The level of serum IFN-γ after treatment increased progressively in responding group, with a significant difference (P<0.05). But it increased slowly in non-responding group, with no significant difference (P>0.05). ③ The level of serum IL-4 after treatment decreased progressively in responding group, with a significant difference (P<0.05), but decreased slowly in non-responding group with no significant difference (P>0.05).
Conclusion: Entecavir used to treat patients with HBeAg-positive chronic hepatitis B not only suppressed HBVDNA replication but also promoted the recovery and regulation of the immune system. The mechanisms may be related to reducing HBVDNA loads and decreasing B7-H1 expression.
| Original language | English |
|---|---|
| Pages (from-to) | 655-658 and 689 |
| Journal | Journal of Xi'an Jiaotong University (Medical Sciences) |
| Volume | 35 |
| Issue number | 5 |
| DOIs | |
| State | Published - 1 Sep 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- B7-H1
- Entecavir
- HBeAg-positive
- Immunoregulation
Fingerprint
Dive into the research topics of 'Immunoregulation of entecavir for patients with HBeAg-positive chronic hepatitis B'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver